Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ming-Liang Jin
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
ORCID:
0009-0003-5747-7707
Observed ORCID:
0009-0003-5747-7707
OpenAlex ID:
A5111235966
Modified lymph node ratio improves the prognostic predictive ability for breast cancer patients compared with other lymph node staging systems
2019
·
Ming-Liang Jin
, Yue Gong
, et al.
·
The Breast
·
22
Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
·
Cancer Research
·
11
Table S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S8 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Data from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S1 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S6 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S5 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S4 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Figure S7 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S3 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Table S5 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2025
·
Xiu-Zhi Zhu
, Hu-Yun-Long Zhang
, et al.
Show more works
View as search
Works count:
19
Citation count:
33
H-index:
2
I10-index:
2
Year
Topic
Type